Beam Therapeutics, Inc. (BEAM)
23.99
-0.38
(-1.56%)
USD |
NASDAQ |
Sep 11, 16:00
24.02
+0.03
(+0.13%)
After-Hours: 20:00
Beam Therapeutics Enterprise Value : 1.572B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 1.572B |
| September 10, 2026 | 1.611B |
| September 09, 2026 | 1.694B |
| September 08, 2026 | 1.865B |
| September 04, 2026 | 2.157B |
| September 03, 2026 | 2.137B |
| September 02, 2026 | 2.119B |
| September 01, 2026 | 2.091B |
| August 31, 2026 | 2.134B |
| August 28, 2026 | 2.122B |
| August 27, 2026 | 2.242B |
| August 26, 2026 | 2.212B |
| August 25, 2026 | 2.299B |
| August 24, 2026 | 2.020B |
| August 21, 2026 | 2.168B |
| August 20, 2026 | 2.026B |
| August 19, 2026 | 2.096B |
| August 18, 2026 | 1.838B |
| August 17, 2026 | 1.893B |
| August 14, 2026 | 1.857B |
| August 13, 2026 | 1.832B |
| August 12, 2026 | 1.853B |
| August 11, 2026 | 1.867B |
| August 10, 2026 | 1.911B |
| August 07, 2026 | 1.932B |
| Date | Value |
|---|---|
| August 06, 2026 | 1.908B |
| August 05, 2026 | 1.890B |
| August 04, 2026 | 2.022B |
| August 03, 2026 | 1.770B |
| July 31, 2026 | 1.730B |
| July 30, 2026 | 1.830B |
| July 29, 2026 | 1.781B |
| July 28, 2026 | 1.809B |
| July 27, 2026 | 1.683B |
| July 24, 2026 | 1.686B |
| July 23, 2026 | 1.770B |
| July 22, 2026 | 1.845B |
| July 21, 2026 | 1.913B |
| July 20, 2026 | 1.813B |
| July 17, 2026 | 1.937B |
| July 16, 2026 | 2.026B |
| July 15, 2026 | 2.279B |
| July 14, 2026 | 2.284B |
| July 13, 2026 | 2.296B |
| July 10, 2026 | 2.469B |
| July 09, 2026 | 2.793B |
| July 08, 2026 | 2.903B |
| July 07, 2026 | 3.010B |
| July 06, 2026 | 2.742B |
| July 02, 2026 | 2.687B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Twist Bioscience Corp. | 7.900B |
| Prime Medicine, Inc. | 583.12M |
| Intellia Therapeutics, Inc. | 1.279B |
| Sarepta Therapeutics, Inc. | 2.417B |
| Revolution Medicines, Inc. | 40.91B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -122.68M |
| Revenue (Quarterly) | 0.49M |
| Total Expenses (Quarterly) | 123.17M |
| EPS Diluted (Quarterly) | -1.176 |
| Gross Profit Margin (Quarterly) | -1.00K% |
| Profit Margin (Quarterly) | -25.04K% |
| Earnings Yield | -3.58% |
| Normalized Earnings Yield | -3.535 |